Clinical Data Concert Pharmaceuticals released the results from the phase 1 study of multiple ascending dose CTP-656 for patients with cystic fibrosis and gating mutations.  The study is consistent with the single ascending dose study.  The Company more importantly claims "CTP-656 demonstrated a longer half-life, reduced rate of clearance, substantially increased exposure and greater plasma levels at 24 hours" than the current market drug Kalydeco.